Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,958 GBX | -0.05% | -1.01% | +9.45% |
05-17 | HIKMA PHARMACEUTICALS : Time to capitalise on Hikma’s ongoing (share price) momentum | |
05-03 | Deutsche Bank Starts Hikma Pharmaceuticals Coverage at Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.45% | 5.54B | |
+38.51% | 727B | |
+32.79% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.31% | 205B | |
-5.73% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Hikma Pharmaceuticals : Glenmark Secures Nasal Spray Marketing Approval In 14 European Countries